Study of Clinic-based Versus Self-use of Medical Abortion Pills
Study of Clinic-based Versus Self-use of Medical Abortion Pills
The goal of the study is to determine whether important clinical outcomes differ among women
 who access a combined medical abortion regimen from a pharmacy when compared with those who
 access it from a facility.
Medical abortion with mifepristone and misoprostol within the first 10 weeks of pregnancy is
 safe and highly effective. Investigators aim to assess whether self-use of early (<9 weeks)
 medical abortion using mifepristone with misoprostol results in non-inferior rates of
 clinical outcomes when compared with clinic-based provision of medical abortion.

 The investigators will prospectively recruit women who obtain medical abortion medication
 from pharmacies and clinics. Follow-up will occur by telephone during two phone calls within
 30 days following the woman's abortion. A small number of adolescents will be recruited into
 a qualitative substudy.
Inclusion Criteria:

 Women are eligible for participation if they have purchased abortion medications
 (mifepristone-misoprostol) independently at a pharmacy or received them from a clinic for
 an unwanted pregnancy at less than 9 weeks since her last menstrual period (LMP). She must
 meet the following criteria:

 -  Be at least 15 years of age (may vary by country)

 -  Have a known LMP of less than 9 weeks

 -  No contraindications to medical abortion (list)

 -  Willing and able to give informed consent

 -  Have a mobile phone of which they are the independent user or be willing to be
 followed-up in person

 -  Willing to be contacted with questions about her abortion by telephone (optional
 in-person visit) at 3, 10-14 and 30 days following initial contact.

 -  Resident of country of study.

 Exclusion criteria:

 -  Contraindications to mifepristone-misoprostol

 -  Age <15